For instance, KRASG12V confers greater resistance to EGFR inhibitors in colorectal cancer, while KRASG13D is associated with worse overall survival of colorectal cancer patients treated with standard chemotherapy [53]. This evidence concerns the gene EGFR and colorectal cancer.